Enhanced TDS
Knowde-enriched technical product data sheet
Identification & Functionality
- Ingredient Name
- Food Ingredients Functions
- Pharma & Nutraceuticals Functions
- Ingredients
- Omega -3 Fatty Acid
- Technologies
Features & Benefits
- Food Ingredients Features
Applications & Uses
- Markets
- Applications
- Highly efficient in lower dosages
- MaGOmega delivery form provides greater absorption and oral bioavailability of Omega-3s allowing lower doses to achieve omega-3 health benefits.
- MaGOmega is also a great solution for those who suffer from digestive issues and impaired lipid absorption due to health challenges.
- Algae and Fish sources
Algae
- Vegan DHA Monoglyceride
- Up to 75% DHA
- Exclusive formula suitable for vegan diet
- Schizochytriumn sp – microalgae – sourced from Europe
- Generally Recognized as Safe (GRAS)
MaGOmega Algae sourced
- MAGOmega™0053 Algae
- MAGOmega™0065 Algae
Fish
- Up to 80% Concentration
- Highest ratios available in MAG form – EPA & DHA
MaGOmega Fish sourced
- MaGOmega™6000
- MaGOmega™0070
- MaGOmega™4535
- MaGOmega™5020
- MaGOmega™4030
Technical Details & Test Data
- Greater bioavailability and Digestion Process
Greater bioavailability
Monoglycerides have shown greater bioavailability in the body than triglycerides and ethyl esters, as demonstrated in several studies.
Omega-3 in MAG form has higher oral bioavailability compared to TG or EE forms:
Digestion Process of Omega-3 Fatty Acids
- The most commonly commercialized forms of omega-3s are ethyl ester (EE) and reconstituted triglycerides (TG). Studies evaluating the pharmacokinetics of omega-3 fatty acids esterified in different forms reported that the most bioavailable form is when provided in MAG > TG > EE.
- EE and TG forms need to be break down into smaller components by lipases in the digestion process for absorption in the mucosal cells of the digestive track, whereas monoacylglycerol (MAG) forms, as well as Free Fatty Acids (FFA), are considered as being in a predigested form, ready to be absorbed:
- Results
MaGOmega™ Results
- MaGOmega™ was tested in a pilot study conducted in cystic fibrosis (CF) patients, a health condition that leads to fat malabsorption and malnutrition, and demonstrated that the medical food MAG-DHA (MaGOmega) represents a solution to overcome the impaired absorption of DHA in CF patients:
- Results showed a ~2-fold increase of the DHA levels after 1 month of MaGOmega™ supplementation while a previous clinical study on CF patients using a triglyceride form showed a 1.6-fold increase and after 3 months of supplementation.